The National Institute for Health and Care Excellence

Hidden spine fractures could be spotted earlier after NICE recommendation

NICE is recommending that quick spine checks are added to routine bone scans to help spot hidden fractures earlier and prevent serious complications. Around 70% of spine fractures caused by ...
The National Institute for Health and Care Excellence

Digital platforms recommended to help people manage their asthma

The eight recommended digital technologies are: Asthmahub, Asthmahub for parents, AsthmaTuner, Digital Health Passport, Luscii, myAsthma, RDMP (Respiratory Disease Management Platform) and Smart ...
The National Institute for Health and Care Excellence

New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier

More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.
The National Institute for Health and Care Excellence

NICE recommends new treatment option for highly active multiple sclerosis

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...
National Institute for Health and Care Excellence

Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early management

This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, ...
National Institute for Health and Care Excellence

DMD Care UK’s guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations: NICE review

We have moved NG251 to become a 'NICE Review'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The review itself has not changed. See ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...
National Institute for Health and Care Excellence

Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

Suggested remit: To appraise the clinical and cost effectiveness of tofersen within its marketing authorisation for treating amyotrophic lateral sclerosis caused by superoxide dismutase 1 (SOD1) gene ...
National Institute for Health and Care Excellence

Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...
National Institute for Health and Care Excellence

Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS

The benefits of the new Alzheimer’s drug lecanemab are too small to justify the costs, NICE said in draft guidance published today. Lecanemab (also called Leqembi and made by Eisai) is for slowing ...
National Institute for Health and Care Excellence

Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal)

NICE is unable to make a recommendation about the use in the NHS of enzalutamide (Xtandi) for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because ...
National Institute for Health and Care Excellence

Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because ...